Jasbir S. Seehra: Q1 Revenue $367,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $367,000, consensus $1.69M. "Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities," said Jasbir S. Seehra, President and Chief Executive Officer. "In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc., plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis, broadening the indication opportunity beyond myelodysplastic syndromes."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KROS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KROS
Wall Street analysts forecast KROS stock price to rise
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 11.220
Low
16.00
Averages
21.20
High
27.00
Current: 11.220
Low
16.00
Averages
21.20
High
27.00
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Keros Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: Keros Therapeutics reported a Q1 GAAP EPS of -$1.21, missing expectations by $0.19, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company generated only $0.37 million in revenue for Q1, a staggering 99.8% year-over-year drop, falling short of the $1.32 million forecast, reflecting severe deficiencies in product sales and market demand that could lead to future liquidity issues.
- Negative Market Reaction: The failure to meet earnings expectations may put downward pressure on Keros's stock price, as investor confidence in the company's growth potential is shaken, potentially affecting its ability to raise funds.
- Need for Strategic Reevaluation: Given the dismal financial performance, Keros may need to reassess its business strategy and market positioning to address current challenges and seek new growth opportunities.
See More
Insmed Shares Rise 5.5% Following Positive Competitive Data
- Stock Price Surge: Insmed shares rallied 5.5% to close at $153.32 in the last trading session, with notable trading volume indicating strong market optimism regarding the company's future potential.
- Impact of Competitive Data: This price increase is linked to positive late-stage study results from rival United Therapeutics, which demonstrated that Tyvaso improved forced vital capacity (FVC) by 130.1 mL in idiopathic pulmonary fibrosis patients, indirectly validating the therapeutic potential of treprostinil.
- Product Development Progress: Insmed's TPIP, a prodrug of treprostinil designed for once-daily dosing, is on track to begin a late-stage study in IPF in the second half of 2026, which could significantly enhance its competitive position in the market.
- Financial Expectations: Insmed anticipates a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, while revenues are expected to reach $299.57 million, up 222.7%, indicating strong momentum in revenue growth.
See More
Keros Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Keros Therapeutics reported a net loss of $23.5 million for Q4 2025, significantly down from $46 million in Q4 2024, indicating effective cost control and revenue growth strategies.
- Substantial Revenue Growth: Total revenue for 2025 reached $244.1 million, a dramatic increase from $3.6 million in 2024, primarily driven by licensing revenue from Takeda, showcasing the company's success in commercialization efforts.
- Clinical Development Progress: The pipeline includes Rinvatercept and Elritercept, with a Phase 2 trial for Rinvatercept targeting Duchenne muscular dystrophy set to begin in Q2 2026, reflecting the company's strategic focus on innovative therapies.
- Executive Changes and Financial Position: Keros ended 2025 with cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028, while the appointment of new board members and a Chief Legal Officer will strengthen corporate governance.
See More
Keros Therapeutics Reports 2025 Financial Results and Strategic Updates
- Improved Financial Performance: Keros reported a net income of $87 million for the fiscal year 2025, a significant turnaround from a net loss of $187.4 million in 2024, indicating strong revenue growth and cost management that boosts investor confidence.
- Reduced R&D Expenses: Research and development expenses for Q4 2025 were $17.9 million, down from $45.6 million in Q4 2024, primarily due to the transition of certain R&D costs to Takeda, optimizing resource allocation and enhancing operational efficiency.
- Clinical Trial Advancements: Keros plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy in Q2 2026 and engage regulators on ALS trial design in the second half of 2026, demonstrating a proactive approach to product development and regulatory engagement.
- Leadership Changes: In February 2026, Charles Newton was appointed to the board, and Esther Cho was promoted to Chief Legal Officer, reflecting ongoing improvements in strategic execution and governance structure aimed at enhancing the company's long-term growth potential.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Keros Therapeutics Appoints Charles Newton to Board of Directors
- New Board Appointment: Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026, bringing extensive healthcare finance expertise that will support the company during critical value inflection points in its clinical programs, thereby enhancing its competitive position in the biopharmaceutical industry.
- Strategic Development Support: Newton expressed his intention to leverage his experience in guiding biotechnology companies through growth phases to advance the clinical development of rinvatercept (KER-065), which is expected to provide potential disease-modifying benefits to patients, further driving the company's long-term growth and value creation.
- Executive Transition: Concurrent with Newton's appointment, Carl Gordon, Ph.D., will step down from the Board on March 9, 2026, with Keros CEO Jasbir Seehra thanking Gordon for his contributions, emphasizing the stability and continuity in the company's board member transitions.
- Product Development Outlook: Keros focuses on developing innovative therapeutics targeting the TGF-β protein family, with its lead candidates rinvatercept and elritercept aimed at treating Duchenne muscular dystrophy and myelodysplastic syndromes, showcasing the company's potential and market opportunities in the biopharmaceutical sector.
See More
Keros Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: Keros Therapeutics reported a Q1 GAAP EPS of -$1.21, missing expectations by $0.19, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company generated only $0.37 million in revenue for Q1, a staggering 99.8% year-over-year drop, falling short of the $1.32 million forecast, reflecting severe deficiencies in product sales and market demand that could lead to future liquidity issues.
- Negative Market Reaction: The failure to meet earnings expectations may put downward pressure on Keros's stock price, as investor confidence in the company's growth potential is shaken, potentially affecting its ability to raise funds.
- Need for Strategic Reevaluation: Given the dismal financial performance, Keros may need to reassess its business strategy and market positioning to address current challenges and seek new growth opportunities.
See More
Insmed Shares Rise 5.5% Following Positive Competitive Data
- Stock Price Surge: Insmed shares rallied 5.5% to close at $153.32 in the last trading session, with notable trading volume indicating strong market optimism regarding the company's future potential.
- Impact of Competitive Data: This price increase is linked to positive late-stage study results from rival United Therapeutics, which demonstrated that Tyvaso improved forced vital capacity (FVC) by 130.1 mL in idiopathic pulmonary fibrosis patients, indirectly validating the therapeutic potential of treprostinil.
- Product Development Progress: Insmed's TPIP, a prodrug of treprostinil designed for once-daily dosing, is on track to begin a late-stage study in IPF in the second half of 2026, which could significantly enhance its competitive position in the market.
- Financial Expectations: Insmed anticipates a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, while revenues are expected to reach $299.57 million, up 222.7%, indicating strong momentum in revenue growth.
See More
Keros Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Keros Therapeutics reported a net loss of $23.5 million for Q4 2025, significantly down from $46 million in Q4 2024, indicating effective cost control and revenue growth strategies.
- Substantial Revenue Growth: Total revenue for 2025 reached $244.1 million, a dramatic increase from $3.6 million in 2024, primarily driven by licensing revenue from Takeda, showcasing the company's success in commercialization efforts.
- Clinical Development Progress: The pipeline includes Rinvatercept and Elritercept, with a Phase 2 trial for Rinvatercept targeting Duchenne muscular dystrophy set to begin in Q2 2026, reflecting the company's strategic focus on innovative therapies.
- Executive Changes and Financial Position: Keros ended 2025 with cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028, while the appointment of new board members and a Chief Legal Officer will strengthen corporate governance.
See More
Keros Therapeutics Reports 2025 Financial Results and Strategic Updates
- Improved Financial Performance: Keros reported a net income of $87 million for the fiscal year 2025, a significant turnaround from a net loss of $187.4 million in 2024, indicating strong revenue growth and cost management that boosts investor confidence.
- Reduced R&D Expenses: Research and development expenses for Q4 2025 were $17.9 million, down from $45.6 million in Q4 2024, primarily due to the transition of certain R&D costs to Takeda, optimizing resource allocation and enhancing operational efficiency.
- Clinical Trial Advancements: Keros plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy in Q2 2026 and engage regulators on ALS trial design in the second half of 2026, demonstrating a proactive approach to product development and regulatory engagement.
- Leadership Changes: In February 2026, Charles Newton was appointed to the board, and Esther Cho was promoted to Chief Legal Officer, reflecting ongoing improvements in strategic execution and governance structure aimed at enhancing the company's long-term growth potential.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Keros Therapeutics Appoints Charles Newton to Board of Directors
- New Board Appointment: Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026, bringing extensive healthcare finance expertise that will support the company during critical value inflection points in its clinical programs, thereby enhancing its competitive position in the biopharmaceutical industry.
- Strategic Development Support: Newton expressed his intention to leverage his experience in guiding biotechnology companies through growth phases to advance the clinical development of rinvatercept (KER-065), which is expected to provide potential disease-modifying benefits to patients, further driving the company's long-term growth and value creation.
- Executive Transition: Concurrent with Newton's appointment, Carl Gordon, Ph.D., will step down from the Board on March 9, 2026, with Keros CEO Jasbir Seehra thanking Gordon for his contributions, emphasizing the stability and continuity in the company's board member transitions.
- Product Development Outlook: Keros focuses on developing innovative therapeutics targeting the TGF-β protein family, with its lead candidates rinvatercept and elritercept aimed at treating Duchenne muscular dystrophy and myelodysplastic syndromes, showcasing the company's potential and market opportunities in the biopharmaceutical sector.
See More
